Evidence-Based Care
Slowing Down Myopia
Every dioptre matters. Myopia control aims to slow how much a progressing eye keeps elongating, reducing lifetime risk rather than simply correcting today's blur.
Every dioptre matters. Myopia control aims to slow how much a progressing eye keeps elongating, reducing lifetime risk rather than simply correcting today's blur.
Glasses, contact lenses and standard OrthoK all do the same essential job: they refocus light so a myopic eye sees clearly. What none of them do, on their own, is influence how much that eye keeps growing. For a child whose myopia is still advancing, that distinction matters enormously.
Myopia management exists to address that gap. It uses specific, evidence-based treatments to slow axial elongation itself, aiming to leave a child with less myopia, and meaningfully lower lifetime eye health risk, than they would have had without treatment. We cover how axial length relates to that risk on our Myopia-Related Eye Diseases page.
Myopia control is specifically for anyone whose myopia is still progressing, most often children and teenagers, but increasingly young adults too. Progression, not age alone, is what determines candidacy. Our risk assessment page outlines the factors, such as family history, near work and limited outdoor time, that make progression more likely.
There's a common perception that eye growth, and therefore myopia, stops around age 18. We now believe that's no longer true for a meaningful number of people, with research showing progression can continue into the mid-to-late twenties. In practice, this means we assess actual progression at every review, rather than assuming it has finished based on age.
Each of these has clinical trial evidence behind it. The right one, or combination, depends on the individual child.
Overnight lenses that reshape the cornea while you sleep, correcting vision by day with nothing worn, while slowing axial elongation.
Learn more →Daily soft lenses, worn during waking hours, purpose-built with dual-focus optics shown in clinical trials to slow progression.
Learn more →Everyday spectacle lenses, such as MiyoSMART and Stellest, built with specialised optical designs shown to slow progression in trials.
Learn more →Nightly eye drops that slow progression pharmacologically, often used alone or in combination with a lens-based treatment.
Compare all options →Short, daily at-home sessions using repeated low-level red light. Once considered emerging, it now has multi-year, large-cohort evidence behind it, including sustained axial length control out to five years.
Compare all options →Technology supports clinical judgement, it doesn't replace it. We've seen enough children, across enough treatments, to know that the best outcome comes from matching the treatment to the child, their lifestyle, and how their eyes actually respond, not from recommending whichever product is most familiar. See the full comparison on our Myopia Control Treatments page, and the research behind our approach on our Evidence-Based Treatment page.
Full refraction, eye health check and axial length measurement to establish exactly where your child stands, and how urgently intervention matters.
We talk through the realistic options for your child specifically, including the trade-offs, so the decision is genuinely informed, not just handed down.
Whichever treatment is chosen, we take the time needed to get comfort, fit and vision right before moving to routine reviews.
Regular reviews track axial length and prescription against expected growth. If a treatment isn't working as well as it should, we adjust the plan rather than staying the course by default.
Book a comprehensive myopia assessment to find out whether your child's myopia is progressing, and which evidence-based treatment options genuinely suit them.